Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses

Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?

(2017) E. Palmerini et al.   EUROPEAN JOURNAL OF CANCER

Giant cell tumour of bone in the denosumab era

(2017) Lizz van der Heijden et al.   EUROPEAN JOURNAL OF CANCER

H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant

(2017) Julian Lüke et al.   HISTOPATHOLOGY

Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls

(2017) Pablo Daniel Roitman et al.   HUMAN PATHOLOGY

How safe and effective is denosumab for bone giant cell tumour?

(2017) Costantino Errani et al.   INTERNATIONAL ORTHOPAEDICS

H3F3 mutation status of giant cell tumors of the bone, chondroblastomas and their mimics: a combined high resolution melting and pyrosequencing approach

(2017) Thibault Kervarrec et al.   MODERN PATHOLOGY

Denosumab: an Emerging Therapy in Pediatric Bone Disorders

(2017) Alison M. Boyce   Current Osteoporosis Reports

Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone

(2016) John Wojcik et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma

(2015) Arjen H.G. Cleven et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

A High-grade Sarcoma Arising in a Patient With Recurrent Benign Giant Cell Tumor of the Proximal Tibia While Receiving Treatment With Denosumab

(2015) Luis A. Aponte-Tinao et al.   CLINICAL ORTHOPAEDICS AND RELATED RESEARCH

Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series

(2015) Ilaria Girolami et al.   JOURNAL OF CLINICAL PATHOLOGY

Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone

(2013) Sam Behjati et al.   NATURE GENETICS

Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone

(2012) D. G. Branstetter et al.   CLINICAL CANCER RESEARCH

RANKL, denosumab, and giant cell tumor of bone

(2012) David M. Thomas   CURRENT OPINION IN ONCOLOGY

Suppression of bone formation by osteoclastic expression of semaphorin 4D

(2011) Takako Negishi-Koga et al.   NATURE MEDICINE

Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice

(2009) Hyunsoo Kim et al.   JOURNAL OF CLINICAL INVESTIGATION

Osteoclast–osteoblast communication

(2008) Koichi Matsuo et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS